BACKGROUND: It has been suggested that oral cobalamin (vitamin (B12)) therapy may be an effective therapy for treating cobalamin deficiencies related to food-cobalamin malabsorption. However, the duration of this treatment was not determined. PATIENTS AND METHOD: In an open-label, nonplacebo study, we studied 30 patients with established cobalamin deficiency related to food-cobalamin malabsorption, who received between 250 and 1000 microg of oral crystalline cyanocobalamin per day for at least 1 month. ENDPOINTS: Blood counts, serum cobalamin and homocysteine levels were determined at baseline and during the first month of treatment. RESULTS: During the first month of treatment, 87% of the patients normalized their serum cobalamin levels; 100% increased their serum cobalamin levels (mean increase, +167 pg/dl; P < 0.001 compared with baseline); 100% had evidence of medullary regeneration; 100% corrected their initial macrocytosis; and 54% corrected their anemia. All patients had increased hemoglobin levels (mean increase, +0.6 g/dl) and reticulocyte counts (mean increase, +35 x 10(6)/l) and decreased erythrocyte cell volume (mean decrease, 3 fl; all P < 0.05). CONCLUSION: Our findings suggest that crystalline cyanocobalamin, 250-1000 microg/day, given orally for 1 month, may be an effective treatment for cobalamin deficiencies not related to pernicious anemia.
BACKGROUND: It has been suggested that oral cobalamin (vitamin (B12)) therapy may be an effective therapy for treating cobalamin deficiencies related to food-cobalamin malabsorption. However, the duration of this treatment was not determined. PATIENTS AND METHOD: In an open-label, nonplacebo study, we studied 30 patients with established cobalamin deficiency related to food-cobalamin malabsorption, who received between 250 and 1000 microg of oral crystalline cyanocobalamin per day for at least 1 month. ENDPOINTS: Blood counts, serum cobalamin and homocysteine levels were determined at baseline and during the first month of treatment. RESULTS: During the first month of treatment, 87% of the patients normalized their serum cobalamin levels; 100% increased their serum cobalamin levels (mean increase, +167 pg/dl; P < 0.001 compared with baseline); 100% had evidence of medullary regeneration; 100% corrected their initial macrocytosis; and 54% corrected their anemia. All patients had increased hemoglobin levels (mean increase, +0.6 g/dl) and reticulocyte counts (mean increase, +35 x 10(6)/l) and decreased erythrocyte cell volume (mean decrease, 3 fl; all P < 0.05). CONCLUSION: Our findings suggest that crystalline cyanocobalamin, 250-1000 microg/day, given orally for 1 month, may be an effective treatment for cobalamin deficiencies not related to pernicious anemia.
Authors: J Vidal-Alaball; C C Butler; R Cannings-John; A Goringe; K Hood; A McCaddon; I McDowell; A Papaioannou Journal: Cochrane Database Syst Rev Date: 2005-07-20
Authors: Wendy P J den Elzen; Gerda M van der Weele; Jacobijn Gussekloo; Rudi G J Westendorp; Willem J J Assendelft Journal: BMC Geriatr Date: 2010-06-23 Impact factor: 3.921
Authors: Emmanuel Andrès; Thomas Vogel; Laure Federici; Jacques Zimmer; Ecaterina Ciobanu; Georges Kaltenbach Journal: Curr Gerontol Geriatr Res Date: 2008-05-26
Authors: Monique P H Tillemans; Eline M V J Donders; Sjoerd L Verweij; Ruud T M Van der Hoeven; Kees J Kalisvaart Journal: Curr Ther Res Clin Exp Date: 2014-03-20
Authors: Stefan Markun; Isaac Gravestock; Levy Jäger; Thomas Rosemann; Giuseppe Pichierri; Jakob M Burgstaller Journal: Nutrients Date: 2021-03-12 Impact factor: 5.717